Literature DB >> 12727535

Assessment of precision and concordance of quantitative mitochondrial DNA assays: a collaborative international quality assurance study.

Emma L Hammond1, David Sayer, David Nolan, Ulrich A Walker, Anthony de Ronde, Julio S G Montaner, Helene C F Cote, Michelle E Gahan, Catherine L Cherry, Steven L Wesselingh, Peter Reiss, Simon Mallal.   

Abstract

BACKGROUND: A number of international research groups have developed DNA quantitation assays in order to investigate the role of mitochondrial DNA depletion in anti-retroviral therapy-induced toxicities.
OBJECTIVES: A collaborative study was undertaken to evaluate intra-assay precision and between laboratory concordance of measurements of mitochondrial DNA quantity, as a component of a comprehensive quality assurance project. STUDY
DESIGN: Four laboratories were asked to measure and report mitochondrial DNA and nuclear DNA genome copy number, as well as mitochondrial DNA copy number/cell, for 17 coded aliquots of DNA derived from serial dilutions of pooled DNA from a lymphoblastoid cell line. Samples included masked replicates and five standards. All samples had similar mitochondrial DNA/nuclear DNA ratios. Precision within laboratories was assessed by determining the coefficient of variation of replicates. Concordance between laboratories was assessed by determining the average coefficient of variation of the mean replicate values for each sample. The effect of standardising the assay for these three measurements was also assessed for laboratories A, B and C.
RESULTS: Measurements of mitochondrial DNA and nuclear DNA content for replicate samples varied by an average of less than 6% (based on log(10) values, 72% non-logged values), and measurements of mitochondrial DNA/cell for replicates varied by less than 12% (based on log(10) values, 32% non-logged values), with no improvement of precision after standardisation. Standardisation did significantly improve the concordance of results for measurements of mitochondrial DNA content and mitochondrial DNA/cell. Non-standardised measurements of mitochondrial DNA content for the same sample set varied by 19% between laboratories (based on log(10) values, 96% non-logged values), and after standardisation results varied by less than 3% (based on log(10) values, 54% non-logged values). There was no significant improvement for concordance of measures of nuclear DNA content after standardisation, with results varying by 4.56% between laboratories (based on log(10) values, 45% non-logged values) before standardisation, and by 2.49% (based on log(10) values, 50% non-logged values) after standardisation. Derived values of mitochondrial DNA/cell varied between laboratories by an average of 91% (non-logged, 56% log(10) values) before and by 56% (non-logged, 13% log(10) values) after standardisation.
CONCLUSION: All assays demonstrated good precision. The use of common standards is an important step in improving the comparability of data between laboratories.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12727535     DOI: 10.1016/s1386-6532(02)00134-8

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  10 in total

Review 1.  Collaborative healthcare research: some ethical considerations.

Authors:  Mohsin Raza
Journal:  Sci Eng Ethics       Date:  2005-04       Impact factor: 3.525

2.  Effects of in utero antiretroviral exposure on mitochondrial DNA levels, mitochondrial function and oxidative stress.

Authors:  A C Ross; T Leong; A Avery; M Castillo-Duran; H Bonilla; D Lebrecht; U A Walker; N Storer; D Labbato; A Khaitan; I Tomanova-Soltys; G A McComsey
Journal:  HIV Med       Date:  2011-11-21       Impact factor: 3.180

3.  Quantitative determination of JAK2 V617F by TaqMan: An absolute measure of averaged copies per cell that may be associated with the different types of myeloproliferative disorders.

Authors:  Emma Hammond; Kathryn Shaw; Benedict Carnley; Stephanie P'ng; Ian James; Richard Herrmann
Journal:  J Mol Diagn       Date:  2007-04       Impact factor: 5.568

4.  Accumulation of mitochondrial DNA mutations in human immunodeficiency virus-infected patients treated with nucleoside-analogue reverse-transcriptase inhibitors.

Authors:  Annalise M Martin; Emma Hammond; David Nolan; Craig Pace; Marion Den Boer; Louise Taylor; Hannah Moore; Olga Patricia Martinez; Frank T Christiansen; Simon Mallal
Journal:  Am J Hum Genet       Date:  2003-02-13       Impact factor: 11.025

5.  Quality assessment of human mitochondrial DNA quantification: MITONAUTS, an international multicentre survey.

Authors:  Hélène C F Côté; Mariana Gerschenson; Ulrich A Walker; Oscar Miro; Gloria Garrabou; Emma Hammond; Joan Villarroya; Marta Giralt; Francesc Villarroya; Paola Cinque; Elena Garcia-Arumi; Antonio L Andreu; Marcello Pinti; Andrea Cossarizza
Journal:  Mitochondrion       Date:  2011-02-22       Impact factor: 4.160

6.  Increased mtDNA levels without change in mitochondrial enzymes in peripheral blood mononuclear cells of infants born to HIV-infected mothers on antiretroviral therapy.

Authors:  Grace A McComsey; Minhee Kang; Allison C Ross; Dirk Lebrecht; Elizabeth Livingston; Ann Melvin; Jane Hitti; Susan E Cohn; Ulrich A Walker
Journal:  HIV Clin Trials       Date:  2008 Mar-Apr

7.  Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats.

Authors:  D Lebrecht; A Geist; U-P Ketelsen; J Haberstroh; B Setzer; U A Walker
Journal:  Br J Pharmacol       Date:  2007-05-21       Impact factor: 8.739

Review 8.  The in-depth evaluation of suspected mitochondrial disease.

Authors:  Richard H Haas; Sumit Parikh; Marni J Falk; Russell P Saneto; Nicole I Wolf; Niklas Darin; Lee-Jun Wong; Bruce H Cohen; Robert K Naviaux
Journal:  Mol Genet Metab       Date:  2008-02-01       Impact factor: 4.797

9.  Antiretroviral therapy-induced mitochondrial toxicity: potential mechanisms beyond polymerase-γ inhibition.

Authors:  S Selvaraj; M Ghebremichael; M Li; Y Foli; A Langs-Barlow; A Ogbuagu; L Barakat; E Tubridy; R Edifor; W Lam; Y-C Cheng; E Paintsil
Journal:  Clin Pharmacol Ther       Date:  2014-03-17       Impact factor: 6.875

10.  Peripheral blood leukocyte mitochondrial DNA content and risk of lung cancer.

Authors:  Gregory T Kennedy; Nandita Mitra; Trevor M Penning; Alexander S Whitehead; Anil Vachani
Journal:  Transl Lung Cancer Res       Date:  2022-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.